Cerebrolysin is a multimodal neuropeptide drug derived from porcine brain tissue that crosses the blood-brain barrier. With a fast onset of action, it supports neurorecovery that helps to regain and maintain the independence of patients suffering from stroke, TBI, dementia and cognitive impairment. Cerebrolysin improves the brain’s ability for self-repair by stimulating neurorecovery.

Cerebrolysin is a mixture of peptides derived from the brains of pigs. It is approved in Austria, Russia, China, South Korea, and more than 50 countries globally as an injection for treating stroke, traumatic brain injury, and dementia. It is not, however, approved for use in the United States

Primary Clinical Benefits

Stroke & Brain Trauma Recovery: May aid motor skills and cognitive rehabilitation following ischemic and hemorrhagic strokes or traumatic brain injuries (TBI) by preserving neuronal integrity.
Dementia & Alzheimer's Disease: Clinical trials indicate that higher doses can slow cognitive decline, reduce psychological symptoms, and improve daily functioning in patients with vascular dementia and Alzheimer's disease.
Neuroprotection: Helps mitigate oxidative stress, limits neuronal apoptosis (programmed cell death), and regulates neuroinflammation.